Eloralintide

Cas NO.: 2883634-40-8
Molecular Formula: C201H319N49O65S2
Molecular Weight: 4526.10
Appearance: White Powder
Purity: 99.0%

Function
1. Reduces body weight by decreasing fat mass;
2. Enhances satiety and suppresses appetite;
3. Combines binding to the amylin receptor while maintaining selectivity for the calcitonin receptor;
4. Lowers glucagon levels and improves leptin signaling;
5. Helps regulate blood sugar and reduce energy intake;

Application
It shows promise for use in research on type 2 diabetes and obesity.

Description About Eloralintide
Eloralintide is an investigational amylin receptor (AMYR) agonist developed by Eli Lilly, primarily for the treatment of obese or overweight patients with type 2 diabetes. It works by reducing calorie intake through affecting appetite or increasing satiety.
Eloralintide is a selective, long-acting amylin receptor agonist administered once weekly via subcutaneous injection, demonstrating good tolerability and clear weight loss effects.
Eloralintide is a highly selective amylin receptor agonist, with its core design highlighting significantly higher activity on amylin receptors (including Amylin1R, Amylin2R, and Amylin3R) compared to calcitonin receptors. Amylin is co-secreted with insulin by pancreatic beta cells, and its functions include regulating gastric emptying, enhancing satiety, and suppressing appetite. It not only lowers glucagon and improves leptin signaling but also helps regulate blood glucose and reduce energy intake, making it a natural weight control factor.
Eloralintide is being evaluated as a monotherapy or in combination with tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist, for the treatment of obesity in patients with or without type 2 diabetes.
Furthermore, Eloralintide treatment also leads to improvements in several metabolic indicators, including reduced waist circumference, improved lipid profiles, improved blood glucose levels, and decreased inflammatory markers, suggesting potential benefits for cardiovascular metabolic risk.